Unraveling the Oncogenic Potential of VAV1 in Human Cancer: Lessons from Mouse Models.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
27 04 2023
Historique:
received: 29 03 2023
revised: 23 04 2023
accepted: 24 04 2023
medline: 15 5 2023
pubmed: 13 5 2023
entrez: 13 5 2023
Statut: epublish

Résumé

VAV1 is a hematopoietic signal transducer that possesses a GDP/GTP nucleotide exchange factor (GEF) that is tightly regulated by tyrosine phosphorylation, along with adapter protein domains, such as SH2 and SH3. Research on

Identifiants

pubmed: 37174676
pii: cells12091276
doi: 10.3390/cells12091276
pmc: PMC10177506
pii:
doi:

Substances chimiques

Proto-Oncogene Proteins c-vav 0
VAV1 protein, human 0
Vav1 protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Science. 1992 May 22;256(5060):1196-9
pubmed: 1375396
EMBO J. 1998 Nov 16;17(22):6608-21
pubmed: 9822605
J Pathol. 2003 Apr;199(4):526-33
pubmed: 12635144
Curr Biol. 2014 Jan 6;24(1):86-93
pubmed: 24332539
Immunity. 2000 Feb;12(2):151-60
pubmed: 10714681
Sci Signal. 2014 Apr 15;7(321):ra35
pubmed: 24736456
Cancer Cell. 2017 Nov 13;32(5):608-623.e9
pubmed: 29136506
Mol Cell Biol. 1995 Aug;15(8):4337-46
pubmed: 7623828
Br J Haematol. 2006 Jun;133(6):642-5
pubmed: 16704440
J Invest Dermatol. 2006 Jul;126(7):1442-4
pubmed: 16778811
Cell Commun Signal. 2006 May 18;4:5
pubmed: 16709244
Proc Natl Acad Sci U S A. 2017 Jan 24;114(4):764-769
pubmed: 28062691
PLoS One. 2012;7(1):e29939
pubmed: 22253833
Mol Cell Biol. 1997 Mar;17(3):1346-53
pubmed: 9032261
Nat Cell Biol. 2004 Mar;6(3):268-74
pubmed: 15039778
Proteins. 2010 Mar;78(4):917-31
pubmed: 19938152
Cancer Res. 2015 Jul 15;75(14):2907-15
pubmed: 25977335
Cancers (Basel). 2022 Jul 29;14(15):
pubmed: 35954378
Oncotarget. 2014 Oct 15;5(19):9214-26
pubmed: 25313137
Mol Cell Biol. 2001 Jun;21(11):3763-74
pubmed: 11340169
J Biol Chem. 2004 Apr 30;279(18):18239-46
pubmed: 14764585
Oncogene. 2017 Apr 20;36(16):2202-2214
pubmed: 27893715
Oncogene. 1993 Jul;8(7):1757-63
pubmed: 8510922
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3035-40
pubmed: 10077632
Cell Signal. 2020 Jan;65:109438
pubmed: 31654719
Biochim Biophys Acta. 2006 Aug;1761(8):827-37
pubmed: 16861033
Cells. 2019 Dec 16;8(12):
pubmed: 31888228
Clin Diagn Lab Immunol. 2004 May;11(3):525-31
pubmed: 15138177
J Biol Chem. 2000 Apr 7;275(14):10141-9
pubmed: 10744696
J Exp Med. 1998 Aug 3;188(3):549-59
pubmed: 9687532
Oncotarget. 2015 Oct 6;6(30):28731-42
pubmed: 26353933
EMBO J. 2021 Nov 15;40(22):e108125
pubmed: 34617326
Nature. 1992 Mar 5;356(6364):68-71
pubmed: 1311423
Oncogene. 1998 Sep 24;17(12):1597-606
pubmed: 9794237
Curr Biol. 1998 May 7;8(10):554-62
pubmed: 9601639
Oncotarget. 2015 Feb 10;6(4):2524-37
pubmed: 25426554
Blood. 2020 Dec 24;136(26):3018-3032
pubmed: 32992343
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
Oncogenesis. 2018 Oct 8;7(10):80
pubmed: 30297765
Oncogene. 1992 Apr;7(4):611-8
pubmed: 1565462
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211065877
pubmed: 34894858
J Cell Sci. 2004 Mar 1;117(Pt 7):1259-68
pubmed: 14996945
J Biol Chem. 2010 Jul 23;285(30):23075-85
pubmed: 20457609
J Exp Med. 1998 Dec 7;188(11):2099-111
pubmed: 9841924
Mol Biol Cell. 2005 Jul;16(7):3223-35
pubmed: 15872091
Int J Clin Exp Pathol. 2018 Jan 01;11(1):391-398
pubmed: 31938123
Signal Transduct Target Ther. 2020 Apr 1;5(1):29
pubmed: 32296045
Blood. 2004 Apr 1;103(7):2443-51
pubmed: 14592821
Curr Opin Immunol. 2005 Jun;17(3):267-74
pubmed: 15886116
J Immunol. 1999 Mar 15;162(6):3148-52
pubmed: 10092764
Int J Hematol. 2010 Jan;91(1):69-77
pubmed: 20013323
Nat Genet. 2016 Jun;48(6):607-16
pubmed: 27158780
Int J Biochem Cell Biol. 2009 Jun;41(6):1245-8
pubmed: 19100858
Mol Cell Biol. 2005 May;25(10):4211-20
pubmed: 15870290
J Mol Diagn. 2021 Aug;23(8):929-940
pubmed: 34147695
Cancer Res. 2006 Jun 15;66(12):6183-91
pubmed: 16778192
Mol Cell Biol. 2000 Mar;20(5):1461-77
pubmed: 10669724
Nat Genet. 2014 Feb;46(2):171-5
pubmed: 24413737
Transl Res. 2013 Sep;162(3):181-90
pubmed: 23856093
Bone. 2006 Dec;39(6):1290-301
pubmed: 16950670
Oncol Rep. 2011 May;25(5):1297-306
pubmed: 21344162
Mol Cell Biol. 1991 Apr;11(4):1912-20
pubmed: 2005887
PLoS One. 2013;8(1):e54321
pubmed: 23342133
Oncogene. 1995 Oct 19;11(8):1665-9
pubmed: 7478592
Blood. 2016 Sep 1;128(9):1234-45
pubmed: 27297792
Immunity. 2008 Jan;28(1):88-99
pubmed: 18191593
Mol Cell Biol. 2001 May;21(9):3126-36
pubmed: 11287617
J Immunol. 2003 Sep 1;171(5):2225-32
pubmed: 12928366
Cell. 2000 Sep 1;102(5):625-33
pubmed: 11007481
Leukemia. 2010 Dec;24(12):2072-9
pubmed: 20861914
J Biol Chem. 2002 Nov 22;277(47):45377-92
pubmed: 12228230
J Immunol. 1994 Jun 1;152(11):5429-37
pubmed: 8189062
Biochem Biophys Res Commun. 2017 Apr 29;486(2):571-576
pubmed: 28336434
J Pathol. 2009 Sep;219(1):25-34
pubmed: 19533802
Life Sci Alliance. 2020 Apr 10;3(5):
pubmed: 32277014
Nat Commun. 2021 Mar 22;12(1):1808
pubmed: 33753749
Cancer Genet. 2018 Apr;222-223:20-24
pubmed: 29666004
Cell Death Differ. 2018 Jan;25(1):154-160
pubmed: 29099487
EMBO Rep. 2008 Jul;9(7):655-61
pubmed: 18511940
Oncotarget. 2014 Jun 30;5(12):4320-36
pubmed: 24962430
Biochem J. 1993 Sep 1;294 ( Pt 2):339-42
pubmed: 7690544
Immunity. 2002 Mar;16(3):331-43
pubmed: 11911819
J Clin Invest. 2003 Dec;112(11):1732-40
pubmed: 14660749
Cancer Discov. 2022 Nov 2;12(11):2516-2529
pubmed: 36218325
EMBO J. 1989 Aug;8(8):2283-90
pubmed: 2477241
Oncogene. 2001 Dec 6;20(56):8057-65
pubmed: 11781818
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221146024
pubmed: 36617975
J Biol Chem. 1992 Sep 5;267(25):18021-5
pubmed: 1381360
Cells. 2022 Mar 10;11(6):
pubmed: 35326399
Nature. 1992 Mar 5;356(6364):71-4
pubmed: 1531699
FASEB J. 2005 Feb;19(2):267-9
pubmed: 15546961
Oncogene. 2015 Sep 3;34(36):4746-57
pubmed: 25531316
Cancer Cell. 2005 Jan;7(1):39-49
pubmed: 15652748
Immunity. 2005 Sep;23(3):263-74
pubmed: 16169499
Cell Growth Differ. 1991 Feb;2(2):95-105
pubmed: 2069873
Curr Biol. 1998 May 7;8(10):563-72
pubmed: 9601640
Hematol Oncol. 2010 Sep;28(3):142-50
pubmed: 20155735
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8431-6
pubmed: 8710888
Cell Signal. 2022 Sep;97:110395
pubmed: 35752351
Immunity. 2006 Mar;24(3):305-16
pubmed: 16546099
J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
pubmed: 14519755
Nature. 1997 Jan 9;385(6612):169-72
pubmed: 8990121
Nat Genet. 2015 Nov;47(11):1304-15
pubmed: 26437031
Dev Cell. 2013 Mar 25;24(6):573-85
pubmed: 23537630
Cell Signal. 2004 Jan;16(1):1-11
pubmed: 14607270
Leukemia. 2019 Dec;33(12):2867-2883
pubmed: 31092896
Oncogene. 1992 Mar;7(3):585-7
pubmed: 1549372
Mol Oncol. 2022 Oct;16(19):3533-3553
pubmed: 35895495
Cell Signal. 2006 Nov;18(11):1834-43
pubmed: 16725310
Cell. 2010 Jan 22;140(2):246-56
pubmed: 20141838
Leukemia. 2018 Mar;32(3):694-702
pubmed: 28832024
Cancer Lett. 2007 Oct 8;255(2):241-54
pubmed: 17590270

Auteurs

Batel Shalom (B)

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel.

Yaser Salaymeh (Y)

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel.

Matan Risling (M)

Department of Military Medicine and "Tzameret", Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel.
Medical Corps, Israel Defense Forces, Tel-Hashomer 02149, Israel.

Shulamit Katzav (S)

Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, Hebrew University, Jerusalem 91120, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH